Mary Rinella to Treatment Outcome
This is a "connection" page, showing publications Mary Rinella has written about Treatment Outcome.
Connection Strength
0.712
-
Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2.
Score: 0.068
-
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
Score: 0.067
-
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
Score: 0.057
-
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
Score: 0.055
-
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
Score: 0.033
-
Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
Score: 0.029
-
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis. Med. 2026 May 08; 7(5):101077.
Score: 0.023
-
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1089-1099.
Score: 0.022
-
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
Score: 0.021
-
Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
Score: 0.021
-
Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 12; 60(11-12):1525-1533.
Score: 0.020
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
Score: 0.020
-
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 03 01; 79(3):674-689.
Score: 0.019
-
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023 11; 79(5):1110-1120.
Score: 0.019
-
Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc. 2003 Jul; 58(1):122-7.
Score: 0.019
-
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
Score: 0.019
-
Liver biopsy in living donors. Liver Transpl. 2002 Dec; 8(12):1123-5.
Score: 0.018
-
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616.
Score: 0.017
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
Score: 0.016
-
Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14.
Score: 0.016
-
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
Score: 0.015
-
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
Score: 0.015
-
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
Score: 0.015
-
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
Score: 0.015
-
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855.
Score: 0.015
-
Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. Gastroenterology. 2019 08; 157(2):472-480.e5.
Score: 0.014
-
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
Score: 0.013
-
Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1.
Score: 0.013
-
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 03 24; 391(10126):1174-1185.
Score: 0.013
-
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
Score: 0.008